MA26630A1 - 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
MA26630A1
MA26630A1 MA25582A MA25582A MA26630A1 MA 26630 A1 MA26630 A1 MA 26630A1 MA 25582 A MA25582 A MA 25582A MA 25582 A MA25582 A MA 25582A MA 26630 A1 MA26630 A1 MA 26630A1
Authority
MA
Morocco
Prior art keywords
phenylpyperidines
novel
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
MA25582A
Other languages
English (en)
Inventor
Edward Armer Richard
James Dutton Christopher
Morris Gethin David
Paul Gibson Stephen
Duncan Smith Julian
Tommasini Ivan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA26630A1 publication Critical patent/MA26630A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
MA25582A 1998-05-18 1999-05-17 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant MA26630A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9810671.9A GB9810671D0 (en) 1998-05-18 1998-05-18 Anti-pruritic agents

Publications (1)

Publication Number Publication Date
MA26630A1 true MA26630A1 (fr) 2004-12-20

Family

ID=10832267

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25582A MA26630A1 (fr) 1998-05-18 1999-05-17 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (18)

Country Link
US (1) US6610711B2 (fr)
EP (1) EP1077940B1 (fr)
JP (1) JP2002515486A (fr)
AP (1) AP9901535A0 (fr)
AT (1) ATE271038T1 (fr)
AU (1) AU3531299A (fr)
BR (1) BR9910609A (fr)
CA (1) CA2332538C (fr)
DE (1) DE69918687T2 (fr)
DK (1) DK1077940T3 (fr)
ES (1) ES2230846T3 (fr)
GB (1) GB9810671D0 (fr)
GT (1) GT199900067A (fr)
MA (1) MA26630A1 (fr)
PT (1) PT1077940E (fr)
TN (1) TNSN99095A1 (fr)
WO (1) WO1999059971A1 (fr)
ZA (1) ZA993364B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
KR20040027870A (ko) * 2001-07-05 2004-04-01 시냅틱 파마세틱칼 코포레이션 Ｍｃｈ 선택적인 안타고니스트로서의 치환 아닐린 피페리딘
DE60226161T2 (de) * 2001-10-22 2009-07-02 Pfizer Products Inc., Groton 3-azabicyclo[3.1.0]hexan derivative als antagonisten der opioid rezeptoren
CA2467749A1 (fr) * 2001-11-19 2003-05-30 Elan Pharmaceuticals, Inc. Piperidines et piperazines 3,4-disubstituees, 3,5-disubstituees et 3,4,5-substituees
ES2201908B1 (es) * 2002-05-29 2005-02-16 Laboratorios Del Dr. Esteve, S.A. Pienso suplementado con ketoprofeno y su empleo en el tratamiento de procesos que cursan con fiebre, inflamacion y/o dolor, en un colectivo de animales, de forma simultanea.
MXPA05011070A (es) * 2003-04-14 2005-12-12 Pfizer Prod Inc Derivados de 3-azabiciclo [3.2.1] octano.
FR2872416B1 (fr) * 2004-07-01 2006-09-22 Oreal Utilisation de derives de piperidine pour lutter contre les rides
JP5577021B2 (ja) * 2005-02-17 2014-08-20 アボット・ラボラトリーズ 動物における障害を治療および予防するための薬剤組成物の経粘膜投与
WO2007070760A2 (fr) * 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Composes qui modulent le recepteur cb2
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
US7935715B2 (en) * 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
AU2007300295A1 (en) * 2006-09-25 2008-04-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
EP2195314B1 (fr) * 2007-08-27 2011-03-23 Theravance, Inc. Composes d'alkyl-8-azabicyclo[3.2.1.]octane disubstitutes utilises en tant qu'antagonistes du recepteur opioide mu
WO2009029252A1 (fr) * 2007-08-27 2009-03-05 Theravance, Inc. Composés d'amidoalkyle-8-azabicyclo[3.2.1]octane en tant qu'antagonistes du récepteur opioïde mu
TWI423801B (zh) 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
ES2465621T3 (es) * 2007-08-27 2014-06-06 Theravance, Inc. Compuestos de heteroarilalquil-8-azabiciclo[3.2.1]octano, como antagonistas de los receptores opiodes mu
WO2009061652A1 (fr) * 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Composés modulant le récepteur cb2
CA2730037A1 (fr) * 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Composes sulfones qui modulent le recepteur cb2
CA2737639A1 (fr) 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Composes modulant selectivement le recepteur cb2
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (fr) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Dérivés d'azétidine 2-carboxamide qui modulent le récepteur cb2
EP2480544A1 (fr) * 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Composés à modulation sélective du récepteur cb2
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
CN106278914B (zh) * 2016-08-19 2018-04-13 四川福思达生物技术开发有限责任公司 一种增产胺的合成工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR206937A1 (es) 1974-09-06 1976-08-31 Lilly Co Eli Procedimiento para preparar compuestos de 1-sustituido-4-alquil-4-fenil-piperidina
ES2058265T3 (es) 1987-04-16 1994-11-01 Lilly Co Eli Piperidinas antagonistas de opiaceos.
ZA922180B (en) * 1991-03-29 1993-09-27 Lilly Co Eli Piperidine derivatives
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
GB9507203D0 (en) * 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
JP2001526643A (ja) * 1997-04-18 2001-12-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環

Also Published As

Publication number Publication date
ATE271038T1 (de) 2004-07-15
GT199900067A (es) 2000-11-04
BR9910609A (pt) 2001-01-09
EP1077940A1 (fr) 2001-02-28
WO1999059971A1 (fr) 1999-11-25
US6610711B2 (en) 2003-08-26
ES2230846T3 (es) 2005-05-01
GB9810671D0 (en) 1998-07-15
CA2332538A1 (fr) 1999-11-25
CA2332538C (fr) 2005-08-02
DK1077940T3 (da) 2004-11-01
AP9901535A0 (en) 1999-06-30
PT1077940E (pt) 2004-10-29
DE69918687T2 (de) 2005-07-28
DE69918687D1 (de) 2004-08-19
ZA993364B (en) 2000-12-01
TNSN99095A1 (fr) 2005-11-10
JP2002515486A (ja) 2002-05-28
EP1077940B1 (fr) 2004-07-14
AU3531299A (en) 1999-12-06
US20030078282A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26622A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26654A1 (fr) Pyrrolopyrimidines nouvelles procede pour leur preparation et compositions pharmaceutiques les contenant
MA24529A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant .
MA26598A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur préparation et compositions pharmaceutiques les contenant
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26669A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26468A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26686A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26424A1 (fr) Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26479A1 (fr) Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26653A1 (fr) Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA26499A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
MA26508A1 (fr) Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation.
MA26433A1 (fr) Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26430A1 (fr) 4 (3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26558A1 (fr) Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26740A1 (fr) Derives de 13-methyl-erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26624A1 (fr) Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26707A1 (fr) Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26519A1 (fr) Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.